表3：移动性与行动自由：终末期心脏功能不全儿科患者使用心室辅助装置的院外治疗新方法

数据集获取（Figshare）

• 源站标题：Table_3_Mobility and freedom of movement: A novel out-of-hospital treatment for pediatric patients with terminal cardiac insufficiency and a ventricular assist device.pdf
• DOI：10.3389/fcvm.2022.1055228.s003
• 发布日期：2022-11-16
• 文件数：1 个
• 文件总体积：206.04 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_3_Mobility_and_freedom_of_movement_A_novel_out-of-hospital_treatment_for_pediatric_patients_with_terminal_cardiac_insufficiency_and_a_ventricular_assist_device_pdf/21562011

命令行下载

curl -L -o "Table_3_Mobility and freedom of movement: A novel out-of-hospital treatment for pediatric patients with terminal cardiac insufficiency and a ventricul.pdf" "https://ndownloader.figshare.com/files/38222994"

文件清单

• Table_3_Mobility and freedom of movement: A novel out-of-hospital treatment for pediatric patients with terminal cardiac insufficiency and a ventricul.pdf（206.04 KB）

文件总体积 206.04 KB（源站 API 实测）。

数据说明

BackgroundDue to rapid medical and technological progress, more and more pediatric patients with terminal cardiac insufficiency are being implanted with a ventricular assist device as a bridge to transplant without legal approval for hospital discharge. EXCOR® Active is a recently developed mobile driving unit for the EXCOR® ventricular assist device (EXCOR® VAD) with a long-lasting battery life that can manage small blood pumps, offering improved mobility for pediatric patients. This study strives to elaborate the requirements necessary for a safe home healthcare environment (HHE) for pediatric patients on EXCOR® VAD powered by the EXCOR® Active driving unit.
Materials and methodsPatient- and device-related preconditions (medical, ethical, psychological, technical, structural, organizational) were analyzed with regard to feasibility and safety in three individual patient cases. Included were pediatric patients with terminal cardiac insufficiency in a stable medical condition receiving in-hospital treatment with a univentricular or biventricular EXCOR® VAD powered by EXCOR® Active. Analysis was single-center, data was obtained 05/2020–02/2022.
ResultsA total of three patients on EXCOR® VAD were identified for HHE treatment with the EXCOR® Active driving unit. Switch was performed safely and increased mobility led to improved psychomotor development and improved quality of life. No complications directly related to HHE-treatment occurred. One patient recently underwent an orthotopic heart transplant, one patient remains in HHE, and one patient died due to a complication not related to the HHE. Ethical approval for off-label use was obtained and patients and parents were given the required technical training and psychological support. Caregivers and medical professionals involved in the patients’ care at home were briefed intensely. Remote consultations were implemented and interdisciplinary in-hospital checks reduced to a long-term 4-week-scheme.
ConclusionWhile it is challenging to discharge pediatric patients being treated with a paracorporeal ventricular assist device (EXCOR® VAD) from hospital, it is feasible and can be managed safely with the novel driving u

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fcvm.2022.1055228.s003（source: https://frontiersin.figshare.com/articles/dataset/Table_3_Mobility_and_freedom_of_movement_A_novel_out-of-hospital_treatment_for_pediatric_patients_with_terminal_cardiac_insufficiency_and_a_ventricular_assist_device_pdf/21562011）。